Expert Shares Data for Split Dosing Schedule of Daratumumab in Multiple Myeloma
January 22nd 2019In an interview with <em>Targeted Oncology</em>, Robert M. Rifkin, MD, highlighted the results of a trial evaluating the safety of split-dosing administration of daratumumab in patients with multiple myeloma.
Women With Select Subtypes of HPV at Higher Risk for Developing High-Grade Cervical Cancer
January 4th 2019Findings of a recent study suggest HPV testing should be incorporated into cervical cancer screening programs. The nested case-control Swedish study found that the presence of specific subtypes of HPV, namely HPV-16 and -18, were associated with a higher risk of developing high-grade cervical intraepithelial neoplasia in women under the age of 30.
Expert Highlights Use of CAR T-Cell Therapy in DLBCL
November 28th 2018In an interview with <em>Targeted Oncology</em>, Charalambos Andreadis, MD, MSCE, discussed the use of CAR T-cell therapy in patients with DLBCL, as well as the toxicities associated with each product. He also highlights other promising therapies in the treatment landscape.
Early-Stage, Metastatic Settings Equivalent for Evaluating Biosimilarity
November 7th 2018According to findings of a systematic literature review presented at the 2018 ESMO Congress, the neoadjuvant and metastatic breast cancer settings are appropriate areas to evaluate the equivalence of biosimilars and originator products.
Expert Highlights the Challenges and Treatment Options for Relapsed Multiple Myeloma
May 25th 2018The use of triplet regimens for the treatment of patients with relapsed multiple myeloma has become one of the most favorable treatments recently. OPTIMISMM, a phase III trial, investigated bortezomib and dexamethasone with or without pomalidomide as another triplet regimen option for use in earlier lines of therapy, said Peter Voorhees, MD.<br />
Expert Discusses Potential Expansions to the Treatment Landscape in RCC
March 23rd 2018Treatment of renal cell carcinoma (RCC) is awaiting the potential integration of combinations of immuno-oncology agents like nivolumab (Opdivo) and ipilimumab (Yervoy), or combinations of targeted therapies with checkpoint inhibitors into the treatment paradigm. In an interview with <em>Targeted Oncology</em>, Robert A. Figlin, MD, discusses the expanding RCC armamentarium and balancing the benefits and risks of standard and emerging treatments to achieve optimal outcomes.
Levy Highlights Novel Combinations in NSCLC
March 2nd 2018A novel regimen of immunotherapy, angiogenesis inhibition, and chemotherapy brings promising outcomes for patients with non-small cell lung cancer (NSCLC). The synergic combination, notes Benjamin P. Levy, MD, would be exciting to have in the landscape.